A Phase IV, Multicenter, Open-Label, Single-Arm Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in First Line Treatment of Indian Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 May 2017
At a glance
- Drugs Docetaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Roche
- 01 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2016 Planned End Date changed from 1 Aug 2018 to 1 Sep 2018.
- 03 Oct 2016 Planned primary completion date changed from 1 Aug 2018 to 1 Sep 2018.